BioCardia announces results of its placebo-controlled CardiAMP HF Phase 3 study

BioCardia (BCDA) announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have been accepted for presentation in a late-breaking symposium at the American College of Cardiology 2025 Scientific Sessions, taking place in Chicago, March 29-31, 2025.